Plexision Develops Cellular Biomarkers For Personalized Diagnosis And Drug Development In Solid Organ Transplantationand Immunological Disorders Plexision S First Patented Productthe Pleximmunetm Assaypredicts The Risk Of Transplant Rejectionthe Test Is Based On Patent Pending Technology To Measure Antigen Specific White Blood Cells Testing Services For Transplant Recipients And Drug Developers Are Provided At Plexision S Clia Certifiedcentral Laboratory In Pittsburgh Plexision Currently Offers Cell Based Testing For Personalized Assessment Of Rejection Risk After Solid Organ Transplantation The Pleximmune Blood Test Is The First Such Test Offered For Children With Liver Or Intestine Transplantation
No conferences found for this company.
| Company Name | Plexision Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
